First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

United Kingdom

University College London Hospitals NHS Foundation Trust, London, London

Sarah Cannon Research Institute UK, London

The Christie NHS Foundation Trust, Manchester

Oxford University Hospitals NHS Foundation Trust, Oxford